Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NOA LIFT · 1 trial · 1 indication
The NLFSS is a validated 5-point scale used to assess the severity of nasolabial folds, where higher scores indicate more severe folds.
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| NOA LIFT | EXPERIMENTAL | Participants will receive initial treatment with NOA LIFT injected into the nasolabial folds. Optional touch-up treatment may be administered at Day 31 if optimal aesthetic correction has not been achieved. |
| JUVÉDERM VOLIFT With Lidocaine | ACTIVE_COMPARATOR | Participants will receive initial treatment with JUVÉDERM VOLIFT with Lidocaine injected into the nasolabial folds. Optional touch-up treatment may be administered at Day 31 if optimal aesthetic correction has not been achieved. |
| Name | Type | Description |
|---|---|---|
| NOA LIFT | DRUG | Injection |
| JUVÉDERM VOLIFT with Lidocaine | DRUG | Injection |
Inclusion Criteria: \- Moderate (2) or Severe (3) on the 5-point Nasolabial Fold Severity Scale (NLFSS) for each nasolabial fold (NLF) on evaluator live assessment (both sides must qualify and have the same score) Exclusion Criteria: * Current cutaneous or mucosal inflammatory or infectious proce...